Small vessel disease: mechanisms and clinical implications.
Joanna M Wardlaw, Colin Smith, Martin Dichgans
https://pubmed.ncbi.nlm.nih.gov/31097385/Actively Recruiting
Led by University of Edinburgh · Updated on 2026-09-11
120
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the role and origin of thrombus in people who have had ischemic stroke, including cryptogenic and lacunar types. This study evaluates a special imaging tracer called 18F-GP1 that binds specifically to activated platelets involved in blood clots. The goal is to better understand how thrombosis contributes to different stroke subtypes and to improve patient care through more precise diagnosis. Participants will undergo diagnostic imaging with 18F-GP1 PETCT to detect platelet activation and thrombus presence. Additional tests may include agitated contrast echocardiogram to check for heart shunts or clots, MRI of the head if needed, and ECG monitoring for up to 7 days if atrial fibrillation is not already documented. These evaluations will be done within 21 days of stroke symptom onset to capture acute changes. During the study, participants will have scans and heart rhythm monitoring as part of research and standard care. Researchers will measure the location and amount of platelet activation by comparing imaging signals. They will also analyze platelet activation in various stroke types and its correlation with clinical features. Safety and ability to complete procedures will be monitored, with total participation lasting up to 21 days after stroke onset.
CONDITIONS
The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke
B
Beth Whittington, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Edinburgh
Lead Sponsor
British Heart Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 21 days from stroke onset
Participants undergo imaging tests including 18F-GP1 PET/CT scan, echocardiogram with contrast, MRI head if needed, and heart rhythm monitoring with ECG Holter for up to 7 days if atrial fibrillation is not already detected.
1 to 3 visits depending on tests required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Joanna M Wardlaw, Colin Smith, Martin Dichgans
https://pubmed.ncbi.nlm.nih.gov/31097385/Robert G Hart, Luciana Catanese, Kanjana S Perera...
https://pubmed.ncbi.nlm.nih.gov/28265016/Hans-Christoph Diener, Ralph L Sacco, J Donald Easton...
https://pubmed.ncbi.nlm.nih.gov/31091372/Beth Whittington, Craig Balmforth, Alessandro Giaj Levra...
https://pubmed.ncbi.nlm.nih.gov/42677492/Rong Bing, Marcus-André Deutsch, Stephanie L Sellers...
https://pubmed.ncbi.nlm.nih.gov/35033495/Sun Young Chae, Tae-Won Kwon, Soyoung Jin...
https://pubmed.ncbi.nlm.nih.gov/30617563/Robert G Hart, Mukul Sharma, Hardi Mundl...
https://pubmed.ncbi.nlm.nih.gov/29766772/Linxin Li, Gabriel S Yiin, Olivia C Geraghty...
https://pubmed.ncbi.nlm.nih.gov/26227434/Chanwoo Kim, Jae Seung Lee, Youngjin Han...
https://pubmed.ncbi.nlm.nih.gov/29959214/Jessica Lohrke, Holger Siebeneicher, Markus Berger...
https://pubmed.ncbi.nlm.nih.gov/28302764/University of Edinburgh
Lead Sponsor
British Heart Foundation
Collaborating Sponsor